Disclosure to a Credulous Audience: The Role of Limited Attention

In our model, informed players decide whether or not to disclose, and observers allocate attention among disclosed signals, and toward reasoning through the implications of a failure to disclose. In equilibrium disclosure is incomplete, and observers are unrealistically optimistic. Nevertheless, regulation requiring greater disclosure can reduce observers' belief accuracies and welfare. A stronger tendency to neglect disclosed signals increases disclosure, whereas a stronger tendency to neglect failures to disclose reduces disclosure. Observer beliefs are influenced by the salience of disclosed signals, and disclosure in one arena can crowd out disclosure in other fundamentally unrelated arenas.disclosure; disclosure regulation; limited attention; credulity

On the Forward-Backward Asymmetry of Leptonic Decays of ttˉt\bar{t} at the Fermilab Tevatron

We report on a study of the measurement techniques used to determine the leptonic forward-backward asymmetry of top anti-top quark pairs in Tevatron experiments with a proton anti-proton initial state. Recently it was shown that a fit of the differential asymmetry as a function of $q_{l}\eta_{l}$ (where $q_{l}$ is the charge of the lepton from the cascade decay of the top quarks and $\eta_{l}$ is the final pseudorapidity of the lepton in the detector frame) to a hyperbolic tangent function can be used to extrapolate to the full leptonic asymmetry. We find this empirical method to well reproduce the results from current experiments, and present arguments as to why this is the case. We also introduce two more models, based on Gaussian functions, that better model the $q_{l}\eta_{l}$ distribution. With our better understanding, we find that the asymmetry is mainly determined by the shift of the mean of the $q_{l}\eta_{l}$ distribution, the main contribution to the inclusive asymmetry comes from the region around $|q_{l}\eta_{l}| = 1$, and the extrapolation from the detector-covered region to the inclusive asymmetry is stable via a multiplicative scale factor, giving us confidence in the previously reported experimental results.Comment: 26 pages, 12 figure

Advanced nickel-cadmium batteries for geosynchronous spacecraft

A nickel cadmium battery was developed that can be operated at 80 percent depth of discharge in excess of 10 years in a geosynchronous orbit application, and has about a 30 percent weight savings per spacecraft over present nickel cadmium batteries when used with a 1000 watts eclipse load. The approach used in the development was to replace nylon separators with inert polymer impregnated zirconia, use electrochemically deposited plates in place of conventional chemically precipitated ones, and use an additive to extend negative plate lifetime. The design has undergone extensive testing using both engineering and protoflight cell configurations

Realization of Coherent Optically Dense Media via Buffer-Gas Cooling

We demonstrate that buffer-gas cooling combined with laser ablation can be used to create coherent optical media with high optical depth and low Doppler broadening that offers metastable states with low collisional and motional decoherence. Demonstration of this generic technique opens pathways to coherent optics with a large variety of atoms and molecules. We use helium buffer gas to cool 87Rb atoms to below 7 K and slow atom diffusion to the walls. Electromagnetically induced transparency (EIT) in this medium allows for 50% transmission in a medium with initial OD >70 and for slow pulse propagation with large delay-bandwidth products. In the high-OD regime, we observe high-contrast spectrum oscillations due to efficient four-wave mixing.Comment: 4 pages, 4 figures. V2: modified title, abstract, introduction, conclusion; added references; improved theoretical fit in figure 3(b); shortened slow light theory description; clarified simplicity of apparatus. Final version as published in Phys. Rev.

Relationship of functional gastrointestinal disorders and psychiatric disorders: Implications for treatment

This article revisits the links between psychopathology and functional gastrointestinal disorders such as irritable bowel syndrome (IBS), discusses the rational use of antidepressants as well as non-pharmacological approaches to the management of IBS, and suggests guidelines for the treatment of IBS based on an interdisciplinary perspective from the present state of knowledge. Relevant published literature on psychiatric disorders, especially somatization disorder, in the context of IBS, and literature providing direction for management is reviewed, and new directions are provided from findings in the literature. IBS is a heterogeneous syndrome with various potential mechanisms responsible for its clinical presentations. IBS is typically complicated with psychiatric issues, unexplained symptoms, and functional syndromes in other organ systems. Most IBS patients have multiple complaints without demonstrated cause, and that these symptoms can involve systems other than the intestine, e.g. bones and joints (fibromyalgia, temporomandibular joint syndrome), heart (non-cardiac chest pain), vascular (post-menopausal syndrome), and brain (anxiety, depression). Most IBS patients do not have psychiatric illness per se, but a range of psychoform (psychological complaints in the absence of psychiatric disorder) symptoms that accompany their somatoform (physical symptoms in the absence of medical disorder) complaints. It is not correct to label IBS patients as psychiatric patients (except those more difficult patients with true somatization disorder). One mode of treatment is unlikely to be universally effective or to resolve most symptoms. The techniques of psychotherapy or cognitive-behavioral therapy can allow IBS patients to cope more readily with their illness. Specific episodes of depressive or anxiety disorders can be managed as appropriate for those conditions. Medications designed to improve anxiety or depression are not uniformly useful for psychiatric complaints in IBS, because the psychoform symptoms that sound similar to those seen in psychiatric disorders may not have the same significance in patients with IBS

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.

BackgroundBevacizumab and temsirolimus are active agents in gynecologic tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors.Patients and methodsWe analyzed safety and responses in 41 patients with gynecologic cancers treated as part of a Phase I study of bevacizumab and temsirolimus.ResultsMedian age of the 41 women was 60 years (range, 33-80 years); median number of prior systemic therapies was 4 (1-11). Grade 3 or 4 treatment-related toxicities included: thrombocytopenia (10%), mucositis (2%), hypertension (2%), hypercholesterolemia (2%), fatigue (7%), elevated aspartate aminotransferase (2%), and neutropenia (2%). Twenty-nine patients (71%) experienced no treatment-related toxicity greater than grade 2. Full FDA-approved doses of both drugs (bevacizumab 15mg/kg IV Q3weeks and temsirolimus 25mg IV weekly) were administered without dose-limiting toxicity. Eight patients (20%) achieved stable disease (SD) > 6 months and 7 patients (17%), a partial response (PR) [total = 15/41 patients (37%)]. Eight of 13 patients (62%) with high-grade serous histology (ovarian or primary peritoneal) achieved SD > 6 months/PR.ConclusionBevacizumab and temsirolimus was well tolerated. Thirty-seven percent of heavily-pretreated patients achieved SD > 6 months/PR, suggesting that this combination warrants further study